1. Home
  2. LGI vs BNR Comparison

LGI vs BNR Comparison

Compare LGI & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LGI

Lazard Global Total Return and Income Fund

HOLD

Current Price

$17.59

Market Cap

226.0M

Sector

N/A

ML Signal

HOLD

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$21.60

Market Cap

252.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LGI
BNR
Founded
2004
2014
Country
United States
China
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
226.0M
252.7M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
LGI
BNR
Price
$17.59
$21.60
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
63.8K
30.5K
Earning Date
01-01-0001
06-05-2026
Dividend Yield
7.10%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$111.65
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.95
$2.18
52 Week High
$19.88
$41.72

Technical Indicators

Market Signals
Indicator
LGI
BNR
Relative Strength Index (RSI) 56.44 55.27
Support Level $17.19 $19.72
Resistance Level $17.75 $23.42
Average True Range (ATR) 0.35 1.39
MACD 0.20 0.94
Stochastic Oscillator 96.71 77.46

Price Performance

Historical Comparison
LGI
BNR

About LGI Lazard Global Total Return and Income Fund

Lazard Global Total Return & Inc Fd Inc is a United States-based diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and income. The fund's portfolio of investments consists of different sector investments such as consumer staples, financials, consumer discretionary, healthcare, materials, sovereign debt and others.

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

Share on Social Networks: